4-Methoxy-3.5-di-tert-butyl-benzonitril | 4917-29-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Methoxy-3.5-di-tert-butyl-benzonitril
• 英文别名: 3,5-di(tertbutyl)-4-methoxybenzonitrile；3,5-Ditert-butyl-4-methoxybenzonitrile
• CAS: 4917-29-7
• 化学式: C₁₆H₂₃NO
• 分子量: 245.365
• InChiKey: KHINRPLPVUIXHM-UHFFFAOYSA-N

物化性质

• 熔点：
  75-76 °C(Solv: methanol (67-56-1); water (7732-18-5))
• 沸点：
  340.4±42.0 °C(Predicted)
• 密度：
  0.96±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  33
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-Methoxy-3.5-di-tert-butyl-benzonitril 在 sodium hydride 、 一水合肼 作用下， 生成 3,5-bis(1,1-dimethylethyl)-4-methoxybenzenecarboximidic acid hydrazide
  参考文献：
  名称：

  Design of 5-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,3,4-thiadiazoles, -1,3,4-oxadiazoles, and -1,2,4-triazoles as orally active, nonulcerogenic antiinflammatory agents

  摘要：

  To discover dual inhibitors of 5-lipoxygenase (LO) and cyclooxygenase (CO) with improved pharmacokinetic properties, we have designed and synthesized series of 1,2,4-triazole, 1,3,4-oxadiazole, and 1,3,4-thiadiazole di-tert-butylphenol derivatives which exhibit a wide range of log P (2.3 to >4) and pK(a) (5.5-12) values. From this work 5-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1,3,4-thiadiazole-2(3H)-thione, choline salt (12a, CI-986) was found to be a potent inhibitor of 5-LO (IC50 = 2.8 muM) and CO (IC50= 0.8 muM), orally active in rat models of inflammation and nonulcerogenic.

  DOI：

  10.1021/jm00060a017
• 作为产物：
  描述：

  4-溴-2,6-二叔丁基苯甲醚 、 氰化亚铜 以 N,N-二甲基甲酰胺 为溶剂， 以91%的产率得到4-Methoxy-3.5-di-tert-butyl-benzonitril
  参考文献：
  名称：

  Mapping the Active Site in a Chemzyme: Diversity in the N-Substituent in the Catalytic Asymmetric Aziridination of Imines

  摘要：

  The active site of the aziridination catalyst derived from either the VANOL or VAPOL ligand and B(OPh)(3) is larger than expected and can accommodate not only significant substitution on the diarylmethyl unit of the imine but also that alkyl (but not perfluorylalkyl) substituents on the aryl groups lead to enhanced rates and enantioselection. The screen of diarylmethyl N-substituents on the imine revealed that the 3,5-di-tert-butyldianisylmethyl group (BUDAM) gave exceptionally high asymmetric inductions for imines of aryl aldehydes.

  DOI：

  10.1021/ol802431v

文献信息

• Azaphthalocyanines with fused triazolo rings: formation of sterically stressed constitutional isomers
  作者：Veronika Novakova、Jaroslav Roh、Petr Gela、Jiří Kuneš、Petr Zimcik

  DOI：10.1039/c2cc30942d

  日期：——

  The presented work deals with synthesis and isolation of constitutional isomers of triazolo-fused azaphthalocyanines. Distribution of the isomers did not follow the statistical calculations due to steric effects of the substituents preferring the least sterically stressed C4h isomer.

  本研究涉及合成和分离三唑并酞菁的同分异构体。由于取代基的立体效应，异构体的分布并不符合统计计算，而是倾向于立体压力最小的 C4h 异构体。
• Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators
  申请人：Adams Alan D.

  公开号：US20090030012A1

  公开（公告）日：2009-01-29

  The invention encompasses compounds of Formula I or pharmaceutically acceptable salts thereof, which are modulators of the CXCR3 chemokine receptor function useful for the treatment or prevention of pathogenic inflammatory processes, autoimmune diseases or graft rejection processes. Methods of use and pharmaceutical compositions are also encompassed.

  这项发明涵盖了Formula I的化合物或其药用盐，这些化合物是CXCR3趋化因子受体功能的调节剂，可用于治疗或预防病原性炎症过程、自身免疫疾病或移植排斥过程。还涵盖了使用方法和药物组合物。
• 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators
  申请人：Samuel Rachel G.

  公开号：US20100286191A1

  公开（公告）日：2010-11-11

  The invention encompasses compounds of Formula I or pharmaceutically acceptable salts thereof, which are modulators of the CXCR3 chemokine receptor function useful for the treatment or prevention of pathogenic inflammatory processes, autoimmune diseases or graft rejection processes. Methods of use and pharmaceutical compositions are also encompassed.

  本发明涵盖公式I的化合物或其药学上可接受的盐，它们是CXCR3趋化因子受体功能调节剂，可用于治疗或预防病原体炎症过程、自身免疫性疾病或移植排斥过程。本发明还涵盖使用方法和制药组合物。
• WO2007/70433
  申请人：——

  公开号：——

  公开（公告）日：——
• Yoshida, Kunihisa; Takeda, Kazusada; Fueno, Takayuki, Journal of the Chemical Society. Perkin transactions I, 1993, # 24, p. 3095 - 3098
  作者：Yoshida, Kunihisa、Takeda, Kazusada、Fueno, Takayuki

  DOI：——

  日期：——